{"name":"Vedanta Biosciences, Inc.","slug":"vedanta-biosciences-inc","ticker":"","exchange":"","domain":"vedanta.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VE303","genericName":"VE303","slug":"ve303","indication":"Moderate to severe ulcerative colitis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VE800","genericName":"VE800","slug":"ve800","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"VE303","genericName":"VE303","slug":"ve303","phase":"phase_3","mechanism":"VE303 is a live biotherapeutic product that modulates the gut microbiome to treat inflammatory bowel disease.","indications":["Moderate to severe ulcerative colitis"],"catalyst":""},{"name":"VE800","genericName":"VE800","slug":"ve800","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPV0ZGRE5mbDRReVhtN3JWNTdUTWtvTVNHVEZ2Zm5LVkdrakZPM2pRYTZtQWJydUxkN3dsQk8xTVB1OVlwZDNzM2VyYUVhQzBwWm9nTEd5U2VuejBxRXZCZ1l2aGdiM3JnS2RBeHVWZ1RqZGh1d3M4Z0g4YmtYTFFFS2IyN3gxZzdtWnRMaUo5Y29nSzNlX1hGUDM5akF5ekdBSlI0QmxldnhIVGxEalhRbjBGZmxNYW9XYUJWOEdpMEdTeGFwemROMkhNNWdoWmJ4ZE1kQ2ROUjBxSGJLMk03c2xQWDMzbk1Lc05Fc2V1dEJDU3JtaTZIdjFXaHNIX2pVUUNrYXlkcDFhYW1QRktLOV9TWmd0ZVExYlBPUGtnNkFUNTY0aVgwQTQxSFg?oc=5","date":"2026-04-08","type":"regulatory","source":"Barchart.com","summary":"Food Allergy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis AG, Camallergy, Genentech, GI Innovation - Barchart.com","headline":"Food Allergy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | N","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNUWxocS1uZjlveVdGRU85S0lMMDZ1cXZqNHVnNzRUdFZUVGFVWGVmNWtZTElMRTEwb1dlZ2FIT0tvRjlZMUJoTjgwSEtWX0l2aFdGRTgzUFROT3ZsajZEQ0RxSkQ3eDFtZWs3N3JoLWJpTURadkhLSkVYY09Kai02VXBvTUdJS2cyRkRmMlp4S0NVMXA5LVVLcm9Nc1I2R1RBTE5zUTBvckd0QWFYQWxjNFRVVlVIX0ZvSWRrWlhPTmtWT3NZR3hwejRIRDJZUlZxZ05pd0hFbEZndjBuYXllNE5yQThyckQ0dW91aEMyeEhpOWlBTEhKSQ?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE54YTd6U0Z6bkhSVmR3cEFEd2lESjRaQjRpZU1paTR6T1dmQjVJTFJETkd3UXNSaGdja1NQbDFocDVaZHV0M0NyRThZT2REM1RWYldvMTJQanRiYS00NzEzVTB1Njl1bEpOQ19ST0x6cmUzTlRKZ2pOZDQtNnI?oc=5","date":"2026-03-31","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNTzlwTmlLWVJzSHh4MUQyZUMtYTA1REZ6dHFzamFiRTQtaTdiMW1sVzFDUUtjci1wSlhlcGVxVVZKTWd2Vi1oT05hR2NWWmtjQ2VBZldtRFRmSnVucDNnNmh0MTd0QUJQSHVhUFlmTE9fU0lTN1VMRDM0TzBvMzdIT01zSTMyeTd3T3oyVjBoOUZuWG9TWFUw?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Diarrhea Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight - openPR.com","headline":"Diarrhea Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxObHBqaS1MMUVBWEwtY2tlblZpb0t5RUR4cy1DclFRMHZhcFo5WlVJNUJsUmhlU19IbEJIYlBKdWxQcWxPbFlJWk5uWVFGSzdaaEFNQzh3M3d5YUNZS3ZEUGZTLThjcVpYazA1ZV9LVnU3Vk9zUmpkVWNLS0k2TlZJNzVqNkJhRVhGM1laTExnaGEtZHRQeGNUeTB3?oc=5","date":"2026-03-09","type":"pipeline","source":"Fortune Business Insights","summary":"Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights","headline":"Microbiome Therapeutics Market Size, Share | Forecast [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNcFM3WG9fTGJONFVueTFVb3F5YnQwUG9CdUFBS3o5MmJScm54U3Q2ZG1nc3lQRlhLMmVTOFA2RnlPMEJYS0JnTGx0YTB2ejIxY3RSVklhTlNtTlFmUUV6ZWROal9BbFNTNUdWNHZrNXQydDM5bGtkMHJtX3dyWFFDZFRBdVBtWGRXUHNpTXRUMTRJMTF1NlEweVR3dzVmVUl4ZGt1a1NvSjdOSk9qOUxCRmNCOA?oc=5","date":"2026-01-16","type":"pipeline","source":"Fierce Biotech","summary":"Vedanta ‘significantly’ reduces headcount to fund lead program - Fierce Biotech","headline":"Vedanta ‘significantly’ reduces headcount to fund lead program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQY0t4UVROWF9sT0t5OUdYa2NIY0VJbzZualBHUkxWa2ktZHRGVEpiOXJ2N1J6bFJsMjhJSnNPcHpqRGZvb014NnJSQ2NmZFVhZmxqVlF5TjZkbVE2R3FKN3otanBpdEZITnlKWmhiQ0RNVEJhenRaM3FMcUVLMEpQbDRqRzRTVjRmSlVCT2lVMkpDSzR2ZE1aZExSaGhCb0pkc3VB?oc=5","date":"2025-12-15","type":"pipeline","source":"MarketsandMarkets","summary":"North America Human Microbiome Market Report 2026-2031, By Drug & Supplement, Disease, and Geo - MarketsandMarkets","headline":"North America Human Microbiome Market Report 2026-2031, By Drug & Supplement, Disease, and Geo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNQUNTN1I2alRyRTZZUzJEMHRnb3Nrd2RlbVptZkdyTm9RaVBMcEtQU0ZOdGZjVy1RMEpvU3dnOTl2WVdWWlZBSkJLaFk2M0VWeTVSNmVFWjJVMnZoLUFBVUpVbFpDUTB2Y3BUc2FwZkdnUE5TcmU2RGVtZEpDZWpScWQ3Xy0?oc=5","date":"2025-10-24","type":"pipeline","source":"bizjournals.com","summary":"21 Mass. life science companies must pay back tax breaks for failing to meet hiring goals - bizjournals.com","headline":"21 Mass. life science companies must pay back tax breaks for failing to meet hiring goals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPdXV1OU12RFhDNERJQkFFNVpIQW5WejYtTUI0blozMEVpclh3anJRdjdtQy1SbEc0VXdnWGFGSDVrRzM2aENGV05ySmZGODBzT2ZjMHIyMmpvZXVaNXZZSkhBSjFrNVRrelNWdzFZenJvRlV4U1BNSVAzd2ZoUUpZSzZBWk9zZw?oc=5","date":"2025-10-01","type":"pipeline","source":"Precedence Research","summary":"Microbiome Therapeutics Market Development and Global Outlook - Precedence Research","headline":"Microbiome Therapeutics Market Development and Global Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNQnZaOHUwbWFabkV0RFAwSE4tQjNxVG5pNnFGWjFiNHlnbGI5SjBUc1pJblMydnpYN3NoV25ZcGlpdmdLM25nM0JHZVB1dnNGOGpvQjlhZ1Z3SFdFQjFPYWk3TnItRXJHeXRpTXctS1Q3RG5KVjF5MGVWX1d6eXM4RE5leUVMY0MtWUtoV0ZWeHZTb0UwZUM4bG95RkFUS25NWHdSVEwwRVF1OHNocUxiQTJvandOZ0J5aHpjVWlVRGpmYXNnbGtEcUZUQXJnN1Jmd0QxTjlvSFJKS21OY2djaVRhR2R2bnFQRHNBXzB4eDhTX3JNdnM5MWYzNk1Gc3p2WXcwakpNZlAzT3IyZzZaRjFhRG9MUGo5ZnNKODhVNWI4UXdqYV9JTTMtSDQtVEJKWHBvRm5ldDlWczFxWEdYaw?oc=5","date":"2025-09-02","type":"pipeline","source":"PR Newswire UK","summary":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - PR Newswire UK","headline":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPanhjYndnQ2cyZ1hWZGdlanR5WEhLWnVYdGRLUDBSYVJpMG45Sk0xdUhyeW1TN053MlR2bXdHMzBnbk5USGhhMHgyWXdiTlFuNGJVaWk0dUZGSDlieG13TUdBa2toUDlfejRPaTk4d2tVdk9MUUdDRzQ1ZG1pWGZCTk5DYmtoWVI2U3NYX0wtaVhrWElQdXVQTzlYREpHaXVNTUJ2N0NKTGY5T0VRVE85VA?oc=5","date":"2025-08-14","type":"trial","source":"BioPharma Dive","summary":"Vedanta, PureTech’s microbiome startup, to cut staff after study setback - BioPharma Dive","headline":"Vedanta, PureTech’s microbiome startup, to cut staff after study setback","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}